Drug profile · INN
ranibizumab-leyk
NUFYMCO
ranibizumab-leyk (NUFYMCO) is an FDA-listed pharmaceutical active ingredient. Current US regulatory status: approved.
FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — ranibizumab-leyk
- US status
- approved
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.81
Quick answer
ranibizumab-leyk (NUFYMCO) is an FDA-listed pharmaceutical active ingredient. Current US regulatory status: approved.
Key facts
INN ranibizumab-leyk
Brand NUFYMCO
Formulation INJECTION
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Frequently asked questions
What is ranibizumab-leyk?
ranibizumab-leyk (NUFYMCO) is an FDA-listed pharmaceutical active ingredient. Current US regulatory status: approved.
What is the brand name for ranibizumab-leyk?
NUFYMCO is a marketed brand name for ranibizumab-leyk. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ranibizumab-leyk?
ranibizumab-leyk has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.